Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 679.70M P/E - EPS this Y -19.50% Ern Qtrly Grth -
Income -117.25M Forward P/E -5.08 EPS next Y 4.90% 50D Avg Chg -31.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 6.00%
Dividend N/A Price/Book 3.05 EPS next 5Y - 52W High Chg -56.00%
Recommedations 1.90 Quick Ratio 7.74 Shares Outstanding 35.89M 52W Low Chg 218.00%
Insider Own 25.10% ROA -47.89% Shares Float 19.44M Beta -0.54
Inst Own 86.85% ROE -84.42% Shares Shorted/Prior 13.82M/11.20M Price 19.20
Gross Margin - Profit Margin - Avg. Volume 853,767 Target Price 54.43
Oper. Margin - Earnings Date Apr 1 Volume 641,861 Change -7.51%
About Biomea Fusion, Inc.

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Biomea Fusion, Inc. News
03:10 PM Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
08:02 AM Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
08:00 AM Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
03/07/24 7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
03/06/24 Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
02/19/24 Feeling Shut Out? 3 Sizzling Stocks and the Pull-Back Prices to Watch For
02/18/24 3 Speculative Stocks That Could Make Your February Unforgettable
01/09/24 Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
01/08/24 Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
01/02/24 Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/20/23 We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
12/12/23 Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why
12/11/23 Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting
12/09/23 Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
12/08/23 Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
12/07/23 Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
12/05/23 Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
11/27/23 Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024
11/16/23 Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
11/08/23 Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
BMEA Chatroom

User Image Stock_Titan Posted - 3 hours ago

$BMEA Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/BMEA/biomea-fusion-inc-reports-inducement-grants-under-nasdaq-listing-hjq5o2rg6w8u.html

User Image Doorkey Posted - 4 hours ago

$BMEA Almost green

User Image Rob88ynn Posted - 4 hours ago

$BMEA but why???

User Image bayrak Posted - 5 hours ago

$BMEA

User Image BillyBarue Posted - 5 hours ago

$BMEA

User Image Nosh Posted - 04/26/24

$BMEA Will be adding to a starter Monday morning...some people on here...add slowly one or you will bleed to death. Of course all the pumpers "sold long ago". (I don't post often on this one...glty.)

User Image Nosh Posted - 04/26/24

$BMEA Looking to add.

User Image bentleysmom Posted - 04/26/24

$BMEA disaster. Just a bleed to $9-10

User Image Adamo777 Posted - 04/25/24

$BMEA whats the news?

User Image Tomppa Posted - 04/19/24

$BMEA well, feeling pretty stupid with this sh*t

User Image Observationalist Posted - 04/19/24

$BMEA $8.85 almost there 👀

User Image Heroforest Posted - 04/19/24

$BMEA so state street just bought 12.5%? Hum….

User Image BillyBarue Posted - 04/18/24

$BMEA

User Image TeresaTrades Posted - 04/18/24

Largest CALL OI decreases $TSLA $PINS $AAPL $SLB $BMEA

User Image HighBetaAlgorithms Posted - 04/17/24

$BMEA only down 40% this month? Wow bears got screwed here

User Image Tomppa Posted - 04/16/24

$BMEA why is this going to zero ? What is it waiting for to go up ?

User Image Tomppa Posted - 04/16/24

$BMEA why is this doing so bad ? What has made it almost 50% cheaper than about 3 months ago ? Was this some kind of pump&dump victim or something else ?

User Image BillyBarue Posted - 04/12/24

$BMEA 13M shares shorted $SPY

User Image TheEqualizer007 Posted - 04/11/24

$BMEA would you short this????

User Image bayrak Posted - 04/11/24

$BMEA

User Image HoneyBadgerOnTheRun Posted - 04/05/24

$BMEA

User Image BillyBarue Posted - 04/04/24

$BMEA doubled my position here Sold out previously at 17.40

User Image Tomppa Posted - 04/04/24

$BMEA starting to feel sea sick with this one

User Image GreenEnergy2022 Posted - 04/04/24

$BMEA Loading on dips here, its a long hold & not for those without PaYtience

User Image Doorkey Posted - 04/03/24

$BMEA Looking bullish.

User Image RonnyLuthaKang Posted - 04/03/24

$BMEA will it squeeze tho 👀

User Image GreenEnergy2022 Posted - 04/03/24

$BMEA 40% short float? Damn

User Image NoFearHere Posted - 04/02/24

$BMEA getting taken to the Woodshed over earnings apparently watching for bounce 11.18

Analyst Ratings
Oppenheimer Outperform Apr 3, 24
JP Morgan Neutral Apr 2, 24
HC Wainwright & Co. Buy Apr 1, 24
Truist Securities Buy Apr 1, 24
HC Wainwright & Co. Buy Mar 6, 24
Truist Securities Buy Feb 6, 24
Citigroup Buy Dec 8, 23
EF Hutton Buy Aug 1, 23
HC Wainwright & Co. Buy Aug 1, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
A2A Pharmaceuticals, Inc. 10% Owner 10% Owner May 12 Sell 33.84 25,000 846,000 3,625,000 05/17/23
A2A Pharmaceuticals, Inc. 10% Owner 10% Owner May 08 Sell 34.25 250,000 8,562,500 3,650,000 05/10/23
A2A Pharmaceuticals, Inc. 10% Owner 10% Owner Apr 20 Sell 29.1188 200,000 5,823,760 3,900,000 04/26/23
A2A Pharmaceuticals, Inc. 10% Owner 10% Owner Mar 31 Sell 31.25 200,000 6,250,000 4,100,000 04/06/23
A2A Pharmaceuticals, Inc. 10% Owner 10% Owner Aug 16 Buy 13.872 30,684 425,648 4,300,000 08/19/22
A2A Pharmaceuticals, Inc. 10% Owner 10% Owner Jul 21 Sell 11.21 34,658 388,516 4,330,684 07/25/22
A2A Pharmaceuticals, Inc. 10% Owner 10% Owner Jun 24 Sell 11.76 34,658 407,578 4,365,342 06/28/22
Valle Franco Chief Financial Offi.. Chief Financial Officer Jan 14 Buy 8.6767 10,000 86,767 10,000 01/18/22